Effect of Colchicine for the Palliative Management of Hepatocellular Carcinoma

• Status: Completed
• Trial end date: 2019-05-31
• Target enrollment: 0
• Participant gender: All

Summary

This trial is to evaluate the potential of colchicine for the palliative management of hepatocellular carcinoma patients with distant metastasis or large vessel invasion using the Department of Health R.O.C. approved doses and methods of administration.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital
• Treatments: Colchicine

Criteria

Inclusion Criteria:

1. . Patient has at least one of the following criteria: (1) positive for hepatocellular carcinoma evidenced by cytology or pathology, (2) serum alpha-fetoprotein level > 400 ng/mL and has evidence of hepatocellular carcinoma provided by contrast-enhanced computed tomography or magnetic resonance imaging.

2. . Contrast-enhanced computed tomography or magnetic resonance imaging has evidence of distant metastasis or large vessel invasion caused by hepatocellular carcinoma.

3. . Patient has Child A hepatic reserved function

Exclusion Criteria:

1. . There are life-threatening hemorrhage including gastrointestinal hemorrhage and hemorrhage from other vital organs such as lungs or brain.

2. . There are life-threatening bacterial, fungal or viral infection (not included hepatitis B and C virus).

3. . Patient has serum creatinine level > 1.5 mg/dL.

4. . Patient must receive long-term medication of statin or fibrates drugs and these medications can not be changed.

5. . Patient has white blood cell count < 1500/µL, platelet count < 30000/µL or hemoglobin < 9.0 gm/dL after medication.

6. . Pregnant woman or plan to be a pregnant woman

7. . allergy to colchicine or has history of severe side effects caused by colchicine

8. . Patient has received systemic chemotherapy within 2 months before enrollment or plans to receive systemic chemotherapy in the future.

9. . Patient is under or plans to receive Nexavar or other clinical trial testing drug.

10. . Patient has severe malfunction of vital organs and can not participate in this study justified by the doctor in this research team.

11. . Patient is under or plans to receive Chinese traditional medicine or herb drugs.